Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIO · IEX Real-Time Price · USD
5.99
+0.16 (2.74%)
Mar 30, 2023, 10:41 AM EDT - Market open
2.74%
Market Cap 6.89M
Revenue (ttm) n/a
Net Income (ttm) -11.48M
Shares Out 1.15M
EPS (ttm) -10.10
PE Ratio n/a
Forward PE 0.23
Dividend n/a
Ex-Dividend Date n/a
Volume 1,175
Open 5.75
Previous Close 5.83
Day's Range 5.75 - 5.99
52-Week Range 3.90 - 29.04
Beta 1.47
Analysts Buy
Price Target 73.44 (+1,126.04%)
Earnings Date May 10, 2023

About PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that t... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Robert J. Bitterman
Employees 12
Stock Exchange NASDAQ
Ticker Symbol PHIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $73.44, which is an increase of 1,126.04% from the latest price.

Price Target
$73.44
(1,126.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

– Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma – – Received confirmation from the FDA th...

1 week ago - PRNewsWire

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

MARLBOROUGH, Mass. , Feb. 22, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to ...

1 month ago - PRNewsWire

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

MARLBOROUGH, Mass. , Feb. 13, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to ...

1 month ago - PRNewsWire

Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

MARLBOROUGH, Mass. , Feb. 10, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to ...

1 month ago - PRNewsWire

Phio Pharmaceuticals Announces Reverse Stock Split

MARLBOROUGH, Mass. , Jan. 25, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to ...

2 months ago - PRNewsWire

Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make im...

2 months ago - PRNewsWire

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors

MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the FDA that...

2 months ago - PRNewsWire

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

MARLBOROUGH, Mass. , Dec. 21, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASY...

3 months ago - PRNewsWire

Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates

Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

4 months ago - Zacks Investment Research

Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update

New executive team leading development of Phio's RNAi compounds and proprietary INTASYL™ platform Continuing enrollment in its Phase 1b study of PH-762 for the treatment of advanced melanoma Additiona...

4 months ago - PRNewsWire

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF. INTASYL™ compounds demonstrated preclinical activity in both Direct-to-Tu...

5 months ago - PRNewsWire

What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock

Phio Pharmaceuticals Corp. (PHIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MARLBOROUGH, Mass. , Oct. 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...

6 months ago - PRNewsWire

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman

MARLBOROUGH, Mass., Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprie...

6 months ago - PRNewsWire

Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

MARLBOROUGH, Mass. , Sept. 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propri...

6 months ago - PRNewsWire

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MARLBOROUGH, Mass., Sept. 12, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprie...

7 months ago - PRNewsWire

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subj...

8 months ago - PRNewsWire

Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting

MARLBOROUGH, Mass. , June 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...

10 months ago - PRNewsWire

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

MARLBOROUGH, Mass. , May 16, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...

11 months ago - PRNewsWire

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass. , Ma...

11 months ago - PRNewsWire

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprieta...

11 months ago - PRNewsWire

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

MARLBOROUGH, Mass. , May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprieta...

11 months ago - PRNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022

Marlborough, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietar...

11 months ago - PRNewsWire

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

MARLBOROUGH, Mass. , May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprieta...

11 months ago - PRNewsWire

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma

MARLBOROUGH, Mass. , April 26, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propri...

1 year ago - PRNewsWire